Clinical Trial

A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 11, 2025 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
A study to evaluate efficacy and safety of transarterial chemoembolization (TACE) in combination with Camrelizumab and Rivoceranib (Apatinib) therapy in patients with incurable hepatocellular carcinoma.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-04-02; most recent amendment 2025-12-10.
Status change: Recruiting → Active, Not Recruiting 2025-12-10
Status change: Not Yet Recruiting → Recruiting 2022-10-17
Trial Details
NCT Number NCT05320692
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Hepatocellular Carcinoma
Enrollment 423 participants
Start Date 2022-08-09
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-11